Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Ijichi

Showing results (61-70 of 111) with videos related to

Pageof 12
Sort By:
Cell Death & Disease|January 20, 2021
Inhibition of histone methyltransferase G9a attenuates liver cancer initiation by sensitizing DNA-damaged hepatocytes to p53-induced apoptosisTakuma Nakatsuka, Keisuke Tateishi, Hiroyuki Kato, et al.
Oncogene|December 14, 2004
Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-betaAmarsanaa Jazag, Hideaki Ijichi, Fumihiko Kanai, et al.
World Journal of Gastroenterology|October 14, 2005
Cancer-derived VEGF plays no role in malignant ascites formation in the mouseBayasi Guleng, Keisuke Tateishi, Fumihiko Kanai, et al.
Cancer Chemotherapy and Pharmacology|September 3, 2013
A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancerNaminatsu Takahara, Hiroyuki Isayama, Yousuke Nakai, et al.
Plos One|November 11, 2020
Inhibition of transforming growth factor-β signaling in myeloid cells ameliorates aortic aneurysmal formation in Marfan syndromeHironori Hara, Sonoko Maemura, Takayuki Fujiwara, et al.
Investigational New Drugs|October 23, 2020
A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxelKei Saito, Yousuke Nakai, Naminatsu Takahara, et al.
Cancer Genomics & Proteomics|October 25, 2020
Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic CarcinogenesisHiroyuki Kato, Keisuke Tateishi, Hiroaki Fujiwara, et al.
Journal of Cancer Research and Clinical Oncology|November 16, 2014
The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patientsYousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, et al.
Biochemical and Biophysical Research Communications|March 25, 2010
Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletionYoshinari Asaoka, Motohisa Tada, Tsuneo Ikenoue, et al.
Cancer Chemotherapy and Pharmacology|October 15, 2013
A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancerYousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, et al.
Pageof 12

Showing results (61-70 of 111) with videos related to

Sort By:
Pageof 12
Cell Death & Disease|January 20, 2021
Inhibition of histone methyltransferase G9a attenuates liver cancer initiation by sensitizing DNA-damaged hepatocytes to p53-induced apoptosisTakuma Nakatsuka, Keisuke Tateishi, Hiroyuki Kato, et al.
Oncogene|December 14, 2004
Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-betaAmarsanaa Jazag, Hideaki Ijichi, Fumihiko Kanai, et al.
World Journal of Gastroenterology|October 14, 2005
Cancer-derived VEGF plays no role in malignant ascites formation in the mouseBayasi Guleng, Keisuke Tateishi, Fumihiko Kanai, et al.
Cancer Chemotherapy and Pharmacology|September 3, 2013
A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancerNaminatsu Takahara, Hiroyuki Isayama, Yousuke Nakai, et al.
Plos One|November 11, 2020
Inhibition of transforming growth factor-β signaling in myeloid cells ameliorates aortic aneurysmal formation in Marfan syndromeHironori Hara, Sonoko Maemura, Takayuki Fujiwara, et al.
Investigational New Drugs|October 23, 2020
A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxelKei Saito, Yousuke Nakai, Naminatsu Takahara, et al.
Cancer Genomics & Proteomics|October 25, 2020
Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic CarcinogenesisHiroyuki Kato, Keisuke Tateishi, Hiroaki Fujiwara, et al.
Journal of Cancer Research and Clinical Oncology|November 16, 2014
The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patientsYousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, et al.
Biochemical and Biophysical Research Communications|March 25, 2010
Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletionYoshinari Asaoka, Motohisa Tada, Tsuneo Ikenoue, et al.
Cancer Chemotherapy and Pharmacology|October 15, 2013
A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancerYousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, et al.
Pageof 12